Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Published 15 September 2009, doi:10.1136/bmj.b3680
Cite this as: BMJ 2009;339:b3680
M Erlewyn-Lajeunesse, consultant in paediatric allergy 1, N Brathwaite, consultant in paediatric allergy2, J S A Lucas, honorary consultant in allergy and respiratory paediatrics, senior lecturer in child health1,3, J O Warner, professor of child health4
1 Southampton University Hospitals NHS Trust, Southampton , 2 Kings College Hospital, London, 3 Infection Inflammation and Immunology, School of Medicine, University of Southampton, Southampton, 4 Imperial College and Imperial College Healthcare NHS Trust, London
Correspondence to: M Lajeunesse, The Childrens Allergy Clinic, Southampton University Hospitals NHS Trust, Southampton SO16 6YD mich.lajeunesse{at}soton.ac.uk
|
Egg allergy affects about 2.6% of preschool children by 3 years of age, and influenza immunisation using egg based vaccines has been classified as a "relative contraindication" (prescribe with extra caution) in this patient group.1 Until now the numbers of children with egg allergy requiring immunisation has been low, but this may change with the potential for a mass immunisation campaign. This article reviews the literature on the safety of flu vaccines and provides guidelines for the administration of these vaccines to children with egg allergy. Although egg-free flu vaccines are expected to be available for this season, the provision of sufficient amounts of this vaccine cannot be guaranteed at the time of writing, and a pragmatic strategy for the safe immunisation of children with egg allergy is required.
We identified articles using PubMed and the search terms "influenza" and "egg allergy". We identified further references within relevant papers. We found two randomised clinical trials, but most evidence comes from small case series.
This season two varieties of flu vaccine will be available: a pandemic A/H1N1 strain and the normal trivalent seasonal flu vaccine that will contain an A/H1N1 virus but will not protect against the pandemic strain. There is an egg-free flu vaccine for seasonal immunisation, and it is anticipated that there will be one available for the pandemic strain (table 1
). These egg-free vaccines are produced using new viral culture techniques in a mammalian cell line.2 3 Inactivated, split flu virus, split virion, subunit, or surface antigen flu vaccines are grown in hens eggs and contain residual allergenic egg white proteins. Some but not all of last seasons flu vaccines (2008) reported maximum egg protein content above the proposed safety cut-off of 1.2 µg/ml, with levels up to 2 µg/ml. Virosomal vaccines are highly purified, and although still grown in egg cultures, often have much less residual egg protein.4
|
According to the Department of Health guidance on immunisation in the Green Book and manufacturers product characteristics, flu immunisation is contraindicated by a confirmed anaphylaxis to a previous dose of the vaccine, to any component of the vaccine, or to egg products.5 Despite the use of anaphylaxis as a severity cut-off, flu vaccines have been used cautiously in individuals with egg allergy. We will look at the evidence for each of these contraindications in turn.
Anaphylaxis as an adverse event after immunisation is a rare event at about one in a million doses.6 7 There is a paucity of published data on the risk of allergic reaction to flu vaccine.8 A large population based study in the United States in 1976 found 11 episodes of non-fatal anaphylaxis in 48 million doses.9 None of the patients with an anaphylaxis to the flu vaccine reported a history of egg allergy.
Excipients in the vaccine can act as allergens in sensitised individuals, as seen with gelatin in the measles, mumps, and rubella vaccine (MMR vaccine) during the 1990s.10 Common residues of production found in flu vaccines include the stabiliser polysorbate 80 and antibiotics such as gentamicin, neomycin, kanamycin, and polymyxin B. There are no reports of anaphylaxis to flu vaccine caused by sensitivity to these agents.
All reported cases of anaphylaxis after flu immunisation in individuals with egg allergy occurred over 20 years ago. At least one case of fatal anaphylaxis after influenza vaccine occurred in a child with egg allergy during the 1970s.11 In 1946 Ratner and Untracht described two cases of adult anaphylaxis related to flu vaccine and egg intolerance from their literature review; they also documented two children who had immediate allergic reactions to full strength intradermal testing with flu vaccine.12 The egg content of the vaccines causing these reactions was likely to have been much higher than those available today. The ovalbumin content of flu vaccines has been shown to change by manufacturer and by year.13 14 More recently, manufacturers have published the maximum egg content of their vaccines in their "summary of product characteristics," which helps to make an assessment of their safety in egg allergy.
Several reports have been published of the safe immunisation of individuals allergic to egg with flu vaccines containing egg (table 2
). Initial case series excluded all who had a positive skin prick or intradermal testing to the flu vaccine.11 15 16 Later case series showed that positive skin and intradermal tests to the vaccine did not predict reactivity, and that individuals with an anaphylaxis to egg have been immunised safely using a split dose protocol (six dose or two dose).17 18 19
|
Although these studies have cautiously established the safety of flu vaccines in a small sample of individuals with egg allergy, the studies are too small to establish the risk of anaphylaxis; however, all subjects tolerated a cumulative full dose of vaccine.
The current guidance has interpreted these data in different ways.14 21 22 The American Academy of Paediatrics Red Book has recommended a graded, five injection protocol after an initial 0.05 ml of 1:10 vaccine dilution, in a setting with full resuscitation facilities.22 Two variations of a two dose, split protocol have also been recommended: one using a 1:100 intradermal test before dosing, whereas the other forgoes diagnostics but excludes those with anaphylaxis to egg.14 21 Neither of these guidelines incorporates the evidence for the safe administration of vaccine either to those with anaphylaxis to egg or to those apparently sensitised to the vaccine (with a positive intradermal test) using a two dose split protocol.19 The British Society of Allergy and Clinical Immunology has recently ratified guidelines based on our advice to members of the Paediatric Allergy Group for the 2008 flu season, which form the basis of our recommendations.23
Given the likelihood of mass immunisation to flu, including preschool children, a pragmatic approach is essential to ensure that individuals with egg allergy are protected, both from the disease and from the risks of immunisation.
Egg allergy is easily diagnosed from a clear history of immediate allergic reaction to egg or to a food containing egg. All children with immediate reactions to egg, including those with localised rashes on exposure, should have skin prick testing or estimation of specific IgE to confirm the diagnosis. Specialist advice may be needed if the diagnosis remains uncertain. We have outlined clinical decision steps in the algorithm (figure
).
|
Many children outgrow their egg allergy in the first few years of life. If a child can eat lightly cooked egg (such as a spoonful of scrambled egg) without reaction then they are no longer allergic. We do not recommend testing children allergic to egg by a trial at home of food containing egg because of the risk of an unsupervised allergic reaction. A specialist should assess a childs current sensitivity. Children tolerating egg in baked products (such as cake) but not boiled or scrambled egg are still potentially at risk of severe reaction.
We recommend that all individuals with egg allergy should be immunised with a mammalian culture based flu vaccine (table 1
). If a mammalian cell culture vaccine is not available then we recommend using a virosomal vaccine for seasonal flu as this has the lowest egg content of any vaccine based on hens egg and has clinical data to support its use.20
Flu vaccines that contain egg should be used with caution and only if other vaccines are not available. A careful assessment should weigh the risks of immunisation against risk of infection with the flu virus. The risk-benefit for each individual will depend on host factors such as underlying chronic illness and current or planned immunosuppression and on viral factors such as the local prevalence and virulence of the seasonal or pandemic virus. In keeping with available safety data, the vaccine should have a stated maximum egg content of <1.2 µg/ml (0.6 µg per dose).19 The ovalbumin content of the pandemic vaccine Pandemrix (GSK) is not known. We recommend that the maximum egg concentration is added to the "summary of product characteristics" before its licensure.
Adverse events to any flu vaccine should be reported to the Medicines Healthcare Regulatory Agencys Yellow Card scheme (http://yellowcard.mhra.gov.uk).
Children with positive allergy diagnostics to egg by skin prick testing or specific IgE estimation have the potential for a generalised reaction when presented with allergen via the parenteral route of intramuscular immunisation, even if reactions on oral exposure have been mild. Until better safety data are available we recommend that these individuals are immunised in a facility with staff experienced in treating children with anaphylaxis, most likely secondary care.
We have divided individuals with egg allergy into two risk groups based on our opinion of their potential for anaphylaxis to the vaccine (table 3
).24 Most children with egg allergy have reactions involving the skin. For the easy application of our recommendations we have simplified the diagnosis of anaphylaxis.25 26 If any uncertainty remains about the nature of the allergic reaction they should be considered to be in the higher risk group.
|
As an arbitrary cut-off we have used step 3 of the British Thoracic Society/SIGN guidelines, where a long acting β2 agonist is added to inhaled corticosteroid therapy.28 Children who have uncontrolled asthma should also be included in the higher risk group. We do not recommend that children with acute asthma are immunised; it should be deferred until they have recovered.
We recommend that high risk children should always be immunised in secondary care owing to the availability of advanced paediatric resuscitation facilities. Unlike normal immunisation advice to wait for 20 minutes after the procedure, we advise that higher risk patients should remain on the premises for 60 minutes after immunisation, in keeping with standard allergen immunotherapy practice (where allergic reaction is more commonly encountered) and to refrain from strenuous exercise for 24 hours.
The A/H1N1 vaccine is expected to consist of two doses three weeks apart. Both doses should be provided in a centre experienced in the management of anaphylaxis. The second dose of the same vaccine can be given in a single 0.5 ml intramuscular injection provided that the first dose has been tolerated.
|
|
|
Cite this as: BMJ 2009;339:b3680
Competing interests: ME-L has received reimbursement to attend scientific meetings from GSK and Wyeth and has an unrestricted educational grant for Sanofi Pasteur MSD.
Provenance and peer review: Not commissioned; externally peer reviewed.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
StumbleUpon
Technorati What's this?
Read all Rapid Responses